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Signaling pathway screening platforms are an efficient
approach to identify therapeutic targets in cancers that lack
known driver mutations: a case report for a cancer of unknown
primary origin
Pedro Torres-Ayuso 1,2, Sudhakar Sahoo3, Garry Ashton4, Elvira An2, Nicole Simms5, Melanie Galvin5, Hui Sun Leong3,
Kristopher K Frese5, Kathryn Simpson5, Natalie Cook 6, Andrew Hughes6, Crispin J Miller3, Richard Marais7,8, Caroline Dive5,8,
Matthew G Krebs6,8 and John Brognard1,2
Precision medicine aims to tailor cancer therapies to target specific tumor-promoting aberrations. For tumors that lack actionable
drivers, which occurs frequently in the clinic, extensive molecular characterization and pre-clinical drug efficacy studies will be
required. A cell line maintained at low passage and a patient- derived xenograft model (PDX) were generated using a fresh biopsy
from a patient with a poorly-differentiated neuroendocrine tumor of unknown primary origin. Next-generation sequencing, high
throughput signaling network analysis, and drug efficacy trials were then conducted to identify actionable targets for therapeutic
intervention. No actionable mutations were identified after whole exome sequencing of the patient’s DNA. However, whole
genome sequencing revealed amplification of the 3q and 5p chromosomal arms, that include the PIK3CA and RICTOR genes,
respectively. We then conducted pathway analysis, which revealed activation of the AKT pathway. Based on this analysis, efficacy of
PIK3CA and AKT inhibitors were evaluated in the tumor biopsy-derived cell culture and PDX, and response to the AKT inhibitor
AZD5363 was observed both in vitro and in vivo indicating the patient would benefit from targeted therapies directed against the
serine/threonine kinase AKT. In conclusion, our study demonstrates that high throughput signaling pathway analysis will
significantly aid in identifying actionable alterations in rare tumors and guide patient stratification into early-phase clinical trials.
npj Genomic Medicine  (2018) 3:15 ; doi:10.1038/s41525-018-0055-6
INTRODUCTION
The application of precision medicine into clinical practice has
substantially impacted the management of cancer over the last
decade. Next-generation sequencing (NGS) technologies allow the
identification of actionable mutations in tumors, to which targeted
therapies can be developed with the potential to improve
therapeutic index to specifically target the tumor versus normal
tissues in contrast to conventional cytotoxics. Increasingly, NGS of
patient tumor samples guides patient stratification into clinical
trials, such that only the patients bearing specific molecular
alterations will receive the corresponding targeted therapy.
However, a major hurdle in matching patients to the correct
targeted therapies is the lack of driver mutations in a majority of
tumors that are sequenced in the clinic. This highlights the need
to bring forward cost-effective complementary approaches that
will aid in identifying activated pathways that can be targeted
therapeutically.
The TARGET (Tumor chARacterisation to Guide Experimental
Targeted Therapy) protocol aims to stratify patients based on
genetic alterations identified in tumor specimens and/or
circulating-free DNA. In addition, in vivo drug efficacy studies in
patient-derived xenografts (PDX) and pathway analysis are
performed for a subset of patients. This approach aims to match
patients to the most appropriate and available early-phase clinical
trials according to their molecular alterations to maximize the
chance of patient benefit from targeted therapies1.
Here we describe a case study (TAR007) of a patient with no
smoking history and a poorly-differentiated neuroendocrine
tumor of unknown primary origin. These are rare tumors,
characterized by poor prognosis, and these patients have limited
treatment options. Chemotherapy and/or radiotherapy treatment,
prior to or after surgical resection of detected tumor masses may
be utilized, but there is limited data for the use of targeted
therapies to treat this type of cancer2. In this study, we conducted
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an extensive molecular characterization of a freshly resected
tumor biopsy to identify constitutively activated and druggable
cell survival pathways in this tumor specimen. While whole exome
sequencing (WES) did not show any actionable mutations, PIK3CA
and RICTOR gene amplifications were detected by whole genome
sequencing (WGS). Complementing this approach, we used a
high-throughput platform for analysis of cell signaling pathways
and detected hyperactivation of the AKT signaling axis. Treatment
of the tumor biopsy-derived cell cultures, or a successfully
established PDX model showed response to AKT inhibitors, and
little or no effect of PI3K inhibitors. These results highlight that
combining NGS, signaling pathway analyses, and preclinical drug
efficacy studies can successfully identify activated pathways that
can be targeted therapeutically in rare tumors that lack actionable
driver mutations. In addition, we identify amplified PIK3CA and
RICTOR as potential biomarkers for patients with neuroendocrine
tumors with increased propensity to respond to treatment with
AKT inhibitors.
RESULTS
A patient presented with a poorly-differentiated neuroendocrine
tumor of unknown primary origin, and the tumor was surgically
resected from the right axilla. An experimental pre-clinical study
was designed to identify potentially druggable genetic alterations
(Fig. 1a). Tumor samples were inoculated into NSG mice to
generate a PDX mouse model for use in drug efficacy studies. In
parallel, tumor fragments were frozen for DNA sequencing and a
low passage cell culture was derived after digestion of the tumor
specimen.
WES of the tumor specimen was conducted to identify
targetable alterations in this patient’s tumor, and DNA from white
blood cells was used as a control to exclude germline variants
from the analysis. WES did not reveal any actionable mutations
(Supplemental file 1). WGS was then performed to identify copy
number alterations. WGS analysis from both the tumor specimen
and a PDX-derived sample revealed chromosome deletions at 3p
and 14q, and amplifications in 3q, 5p, 13q, and 17q (Fig. 1b).
Among the regions of amplification, we detected copy number
gains of the PIK3CA (in 3q, 4 copies) and RICTOR (in 5p, 5 copies)
genes, which are upstream activators of the oncogenic kinase AKT.
Fresh tumor biopsy-derived low passage cell cultures were then
used to assess pathways activated in the tumor sample. Normal,
non-transformed, primary cells were used as controls (NHBE and
SAEC; Fig. 1c). Several components of the AKT pathway were
specifically activated in the tumor-derived cells, including AKT,
PRAS40, and GSK3α/β, consistent with this pathway being
activated due to amplification of RICTOR and PIK3CA. High levels
of phosphorylation were also found for the p53 tumor suppressor
protein, and the WNK1 protein kinase (Fig. 1c). Using phospho-
receptor tyrosine kinase (RTK) arrays, hyperactivation of the insulin
receptor was detected. Interestingly, we observed downregulation
of the epithelial growth factor (EGF), insulin-like growth factor 1
(IGF-1), and receptor-like tyrosine kinase (RYK) receptors (Fig. 1d).
Overexpression of PIK3CA, RICTOR, and activation of the AKT
pathway were further confirmed by western blot (Fig. 1e).
Furthermore, positive pAKT staining was detected in the patient’s
biopsy and PDX models by immunohistochemistry, indicating the
AKT pathway was activated, however at lower levels than a PTEN-
negative prostate cancer specimen that was used as positive
control (Figure S1).
Our data indicated that the PI3K/AKT pathway was constitu-
tively activated so inhibitors targeting these kinases were explored
in functional assays. Treatment of the tumor-derived cells with
AZD8835 or GDC0941, two PIK3CA selective inhibitors, had minor
pro-apoptotic effects compared to vehicle-treated cells (Fig. 2a
and S2A). In contrast, treatment of the tumor-derived cells with
two selective AKT inhibitors, AZD5363 (an ATP-competitive
inhibitor), or MK2206 (an allosteric AKT inhibitor) resulted in a
significant increase in cell death (Fig. 2a and S2A). In addition, AKT
inhibition had a strong effect on cell proliferation, and diminished
the percent of proliferating cells (21.1% in vehicle-treated cells;
16.0% in AZD8835-treated cells and 9.0% in AZD5363-treated
cells; Fig. 2b). Time course experiments were then conducted to
investigate mechanisms of sensitivity to AKT inhibitors. Treatment
with the AKT inhibitors, AZD5363 or MK2206, resulted in sustained
inactivation of the AKT substrate PRAS40, this was not the case
with PI3K inhibitors (BKM120, GDC0941, and AZD8835; Fig. 2c, d
and S2B). PRAS40 is a negative regulator of mTORC1, a
multiprotein complex required for cell growth and proliferation.
Phosphorylation of PRAS40 by both AKT and mTORC1 promotes
the dissociation of PRAS40 from mTOR, leading to activation of
mTORC1 (Fig. 2c)3. Decreased phosphorylation of the mTORC1
downstream substrate ribosomal protein S6 (rpS6) was also
observed in cells treated with AKT inhibitors, consistent with
non-phosphorylated PRAS40 binding and inhibiting mTORC1
activation (Figure S2B). Cells treated with PI3K inhibitors did not
display sustained decreased rpS6 phosphorylation (Figure S2B).
Therefore, sustained inactivation of pathways downstream of AKT
in cells treated with AKT inhibitors is likely to account for the
sensitivity observed towards the AKT inhibitors and not to PI3K
inhibitors.
We then expanded these in vitro studies to explore responses in
PDX models. PDX models resembled the original biopsy histology,
as assessed by immunohistochemistry for the neuroendocrine
marker CD56 and the proliferation marker KI67. pAKT staining was
observed at varying levels in different PDX samples, indicative of
intra-tumor heterogeneity (Figure S1A). Consistent with data
derived from the low passage cell cultures, treatment with
AZD5363 in vivo significantly reduced tumor growth by approxi-
mately 50% (Fig. 2e). PI3K inhibition with AZD8835 showed no
significant difference in the tumor growth rate when compared
with the vehicle-treated group (Fig. 2f). Together our data confirm
inhibition of AKT as a viable therapeutic strategy and demonstrate
that molecular pathway analysis and PDX mouse models can be
used in combination to significantly aid in stratifying patients for
treatment with targeted therapies in the absence of known driver
mutations.
DISCUSSION
Here, we report extensive molecular characterization from a high
grade neuroendocrine tumor of unknown primary origin with the
aim of identifying actionable alterations. Increasingly, NGS
approaches, such as WES, are being used in the clinical setting
to facilitate identification of actionable mutations. However, in this
patient case study, WES analysis of the surgical specimen did not
reveal the presence of any targetable genetic alterations.
Amplification of chromosomes 3q and 5p were identified by
WGS; this included copy number gains in the RICTOR and PIK3CA
genes, which correlated with AKT pathway activation. High
throughput technologies analyzing cellular signaling networks,
including phospho-arrays, are being implemented into therapeu-
tic target and biomarker discovery programs4,5. These approaches
aid in identifying signaling networks activated in tumor speci-
mens, as genetic mutations do not always correlate with changes
in protein activity. A cost-effective phospho-array analysis was
used and revealed hyperactivation of the PI3K/AKT pathway,
consistent with amplification of the RICTOR and PIK3CA genes.
A strength of the TARGET protocol is the ability to simulta-
neously generate patient-derived preclinical models in which to
test the efficacy of potential personalized treatments. PDX mouse
models are to date considered to accurately predict tumor
responses, however, it can take a prolonged time to expand the
tumor specimen in animals before any pharmacological study can
be conducted. To overcome this issue, we also established low
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passage tumor-derived cell cultures to test the efficacy of PI3K and
AKT inhibitors based on identification of the activated AKT
pathway by the phospho-array and confirmation by Western blot
analysis. Increased cell death was observed after treatment with
the AKT inhibitors AZD5363 and MK2206, however, little or no
response was observed to PI3K inhibitors. This is in agreement
with recent data, showing that tumors with RICTOR amplification
are frequently refractory to PI3K inhibition6. Sensitivity to AKT
inhibitors might rely on sustained inhibition downstream of AKT
and mTORC1, an effect not observed after PI3K inhibition. Patients
with RICTOR amplification might also benefit from mTOR
inhibitors6; however, these compounds were not tested since
secondary resistance normally appears and involves reactivation
of the PI3K-AKT or the MAPK pathways7,8. Similar responses to AKT
and PI3K inhibitors were observed in our PDX models, indicating
that low passage cell cultures, when possible to generate, can be a
powerful tool for initial inhibitor testing and aid in refining in vivo
experiments. In addition, our data suggest that PIK3CA and RICTOR
gene co-amplification may define a unique subset of patients with
neuroendocrine tumors that will respond to AKT inhibitors, and
could thus be used as an additional biomarker for treatment
stratification.
In this particular patient case there were no available early-phase
clinical trials with an AKT inhibitor recruiting patients with
neuroendocrine tumors. A lack of available relevant clinical trials
to cover all possible identified alterations has been recognized as a
challenge in many precision medicine programs and is a key reason
for only ~5–15% of patients with detected actionable alterations
being matched to relevant targeted therapies9; https://dctd.cancer.
gov/majorinitiatives/NCI-sponsored_trials_in_precision_medicine.htm.
The technological ability to identify actionable targets has
outpaced the speed of change in clinical trial design where a
Fig. 1 Activation of the AKT pathway in a neuroendocrine tumor of unknown primary origin. a Scheme depicting sample collection and
processing for the TARGET clinical trial and the studies performed for the molecular analysis of the tumor specimen TAR007. WBC White
Blood Cells, WG Whole Genome, WE Whole Exome. b Whole genome sequencing from the tumor and a patient-derived sample shows
extensive copy number variations, including amplifications in 3q and 5p chromosomes. c Phosphokinase arrays from tumor-derived low
passage cell cultures show activation of several components of the AKT-mTOR signaling pathway compared to normal primary cells NHBE
(normal human bronchial epithelium) and SAEC (small airway epithelial cells). d Phospho-receptor tyrosine kinase (RTK) arrays from TAR007
low passage-derived cell cultures show different RTK activation profiles. e Western blot confirming overexpression of PIK3CA (aka p110α) and
RICTOR, as well as hyperactivation of AKT in TAR007-derived cell cultures. GAPDH was used as a loading control. Uncropped blots are available
in Figure S3
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more flexible structure is needed to facilitate successful delivery of
precision medicine. We are exploring a framework to this effect
within our own institution for such unique cases where
comprehensive patient-derived pre-clinical data is available and
where no suitable clinical trial or agent is otherwise available.
To date enrollment into clinical trials mostly relies on mutational
status of the corresponding target (e.g., AKT). Our study suggests
that complementation of sequencing approaches with cost-
effective and time-efficient antibody-based technologies, such as
phospho-arrays, can maximize the detection of druggable
Fig. 2 TAR007 patient-derived cancer cells and xenografts (PDX) are sensitive to the AKT inhibitor AZD5363. a Tumor-derived low passage
cells were treated with the indicated inhibitors for 48 h and DNA content was analyzed by propidium iodide staining and flow cytometry. The
percentages of live and dead cells are indicated. Histograms are indicative of 3 independent experiments (N= 3). b Percentage of cells in each
phase of the cell cycle (G0/G1 or S+G2/M) of cells analyzed in a (N= 3 independent experiments). c Scheme of the AKT pathway. d TAR007
cells were treated at 1 μM concentration with the indicated inhibitors for different times and effectors of the AKT-mTOR pathway were
analyzed by western blot. GAPDH was used as a loading control; a representative western blot of N= 3 independent experiments is shown.
Uncropped blots are available in Figure S3. e, f TAR007 PDX (N= 9 mice/group) were treated with e vehicle and AZD5363 or f vehicle and
AZD8835 as described in the methods section, for the days indicated and tumor volume was recorded every 48 h. Data are shown as mean ±
SEM. **P-value < 0.01; *P-value < 0.05
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pathways in tumor cases where no actionable mutations have
been identified or little is known about tumor etiology. Lack of
detection of actionable mutations by sole use of genomic
techniques is a frequent problem in the clinic; recent precision
medicine trials, including the IMPACT and MOSCATO trials, have
reported 44% and 49% of patients with actionable mutations
respectively10,11. In addition, a recent cancer genomics study has
shown that half of driver mutations in tumors occur outside of
well-characterized cancer genes12; such mutations will not be
identified in tumor sequencing studies. Therefore, clinical
implementation of these unbiased signaling pathway analysis
technologies to large patient cohorts or rare tumor cases, such as
the one presented in this study, could improve selection of
patients to early-phase clinical trials of targeted therapies. Such
need to broaden the spectrum of techniques in precision
oncology to detect genetic and non-genetic targetable cancer
vulnerabilities has been recently raised13. Integration of these
technologies into the clinic coupled with modern trial designs that
can adapt to the ‘N of 1’ scenario will aid precision medicine-
based approaches.
METHODS
Patient details
A 68-year old gentleman presented with an isolated right axillary mass in
October 2014. An axillary biopsy revealed poorly-differentiated (Grade 3,
Ki67 85%) neuroendocrine carcinoma of unknown origin (positive for
CD56, chromagranin and synaptophysin; negative for TTF1, CDX2 and
Merkel Cell Polyomavirus). Positron emission technology/computed
tomography demonstrated a right axillary mass and no other identifiable
sites of disease. The patient received six cycles of carboplatin and
etoposide chemotherapy between Oct 2014 and April 2015 with RECIST
partial response after three cycles but with evidence of tumor growth after
cycle 6. He was referred to the Experimental Cancer Medicine Team and
consented to TARGET in June 2015. In parallel he was referred for surgical
resection of the isolated axillary mass which achieved a complete resection
and permitted access to fresh tissue for PDX and translational research in
July 2015.
Following a brief disease-free period, the patient relapsed with
metastatic nodules within the retroperitoneum in December 2015. The
patient was treated with capecitabine and temozolamide between March
and October 2016 with best response of progressive disease. Treatment
was switched to interferon and sandostatin and his disease has remained
stable by RECIST 1.1 criteria on this combination at the time of writing.
Ethical approval
The TARGET protocol and associated translational research analyses were
approved by the North-West Preston Research Ethics Committee, United
Kingdom in February 2015. The patient provided fully informed written
consent to participate in this trial and for the use of donated tumor/blood
samples for research that may help identify personalized therapeutic
options. A blank consent form is provided in the supplementary
information section. Research conducted in this study was performed in
accordance with the Human Tissue Act 2004, and regulations approved by
the Human Tissue Authority at The Christie NHS Foundation Trust
(Manchester, UK). All patient information has been anonymized.
DNA isolation
DNA was extracted from snap frozen tumor specimen, patient-derived
xenograft fragment and tumor-derived cells in culture using the AllPrep
DNA/RNA Mini Kit (Qiagen) according to the manufacturer’s protocol.
Whole exome sequencing
Genomic DNA (1 μg) was sheared in a Covaris S2 ultrasonicator (Covaris
Inc) to an average size of 150–200 bp. Multiplexed libraries were prepared
using the SureSelectXT Target Enrichment System for Illumina Paired-End
Sequencing Library kit and the SureSelect Exome V6+ COSMIC Capture
Library (Agilent). Library quality was checked using the Agilent Bioanalyzer.
Libraries were quantified by qPCR using the KAPA Library Quantification Kit
for Illumina (Kapa Biosystems Inc.). 1.8 pM pooled libraries were loaded
onto the NextSeq 500 and 2 × 76 bp sequencing was carried out using a
NextSeq 500/550 High Output v1 kit (Illumina Inc.).
Whole genome sequencing
Genomic DNA (300 ng) was sheared in a Covaris S2 ultrasonicator (Covaris
Inc) to an average size of 150–200 bp. Multiplexed libraries were prepared
using the NEBNext DNA Ultra kit (New England Biolabs) with an input of
50 ng sheared DNA. Library quality was checked using the Agilent
Bioanalyzer. Libraries were quantified by qPCR using the KAPA Library
Quantification Kit for Illumina (Kapa Biosystems Inc.). 1.8 pM pooled
libraries were loaded onto the NextSeq 500 and 2 × 151 bp sequencing
was carried out using a NextSeq 500/550 Mid Output v2 kit (Illumina Inc.).
Sequencing data processing
Reads were quality checked and aligned to GRCh37/hg19 reference
genome using BWA (v0.7.7)14 with default options. Prior to downstream
analysis, samtools (v1.2)15 were used to retain only uniquely mapped
reads. BAM files were coordinately sorted and de-duplicated via Picard
(v1.96).
Calling variants
Variants were called using GATK (v.3.1.1)16 based upon established best
practices17. Prior to calling variants, local realignment around known indels
was performed on the dedupped, sorted BAM files using realignment
targets from known sites (e.g., dbSNP, 1000 Genomes). Realignment
around indels helps improve the accuracy of the downstream processing
steps. In order to detect systematic errors made by the sequencer when it
estimates the quality score of each base call, base quality score
recalibration was performed. These steps generate the BAM files ready
for variant calling. Variants were called using the UnifiedGenotyper on the
target regions only. The call set produced by GATK was filtered for required
variants using custom scripts. For variant annotation, ANNOVAR18 was
used.
Copy number analysis
HMMcopy (v0.99.0)19 was applied to the dedupped BAM files to detect
copy number change. Briefly, the genome was divided into windows of
fixed size (150 kb) and read count was determined as the number of reads
overlapping each window. GC content and mappability bias correction
were performed on tumor and normal samples, filtering out GC-content
within the top or bottom 1% quantile. The remaining windows with
mappability score greater than 0.9 were kept. The corrected read counts in
each bin were used to calculate the log2ratio. A 6-state Hidden Markov
model (HMM-based) approach was used to segment the data into regions
of similar copy number profile and to predict a copy number alteration
event (i.e., 0, 1, 2, 3, 4 or > 5 copies of chromosome) for each segment.
Animal research
Animal research was approved by the Cancer Research UK-Manchester
Institute Ethical Review Committee, and was performed in accordance with
the Animals (Scientific Procedures) Act 1986 and ARRIVE (Animal Research:
Reporting of In Vivo Experiments) approved guidelines and regulations.
PDX were generated as previously described20,21. Six to eight week-old
Nod.scid.IL2γ (NSG) mice were obtained from Charles River. Tumor volumes
were calculated according to the formula: tumor volume= (length ×
width2)/2. When tumors reached 150mm3, mice (N= 9 per group) were
randomized and drug/vehicle treatments were started. AZD5363 and
AZD8835 were administered by oral gavage at a dose of 150 and 75mg/
Kg, respectively, as previously described22,23. Mice were culled when tumor
volumes reached 800–1000mm3 or after 6 months if there were no signs
of tumor growth.
Low passage cell cultures
A tumor fragment (~1 cm3), from the patient’s original biopsy, was minced
and digested with type I collagenase (100 U/mL; 16 h) in serum-free, 2 ×
Penicillin/Streptomycin RPMI1640; and washed with cold ACK lysis buffer
(Gibco). Cells were filtered through a 40 μm cell strainer and seeded in
HITES medium supplemented with 1% FBS (Labtech). After 24 h, two
populations were distinguished: an adherent one with fibroblast morphol-
ogy which was frozen, and a suspension one which was used for further
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studies and corresponded with tumor material. Cultures were maintained
in HITES for a maximum of 4 weeks (3–4 passages). HITES medium was
prepared by mixing RPMI1640 with Insulin-transferrin-selenium-
ethanolamine and hydrocortisone (10 nM, Sigma). All solutions were
purchased from Gibco unless indicated. SAEC (small airway epithelial cells)
and NHBE (normal human bronchial epithelial) cells were purchased from
Lonza in February 2016 and maintained as recommended for two
passages.
Phospho-arrays
The Proteome Profiler Human Phospho-Kinase and human phospho-
receptor tyrosine kinase (RTK) Array kits (R&D Systems) were used
according to the manufacturer’s instructions.
Reagents and drug treatments
AZD8835 and AZD5363 were kindly provided by AstraZeneca. BKM120,
GDC0941, and MK2206 were purchased from Selleckchem. Drugs were
resuspended in DMSO (10 mM stocks) and used at 1 μM for the times
indicated.
Cell cycle analysis
Cells were seeded (2 × 105 cell/mL) and treated with the corresponding
inhibitors for 48 h. Cells were then collected and treated with trypsin
(Gibco) for 5 min to disperse cell clumps, and spun at 2000 rpm for 3min.
BD Cycletest Plus DNA Reagent Kit was used for sample staining, according
to the manufacturer’s protocol. Samples were run on a BD LSR Fortessa,
and results analyzed using FlowJo.
Western blot
For western blot, cells were lysed as previously described24. Antibodies to
phospho-AKT Thr308 (#2965), phospho-PRAS40 Thr246 (#2997), phospho-
ribosomal protein S6 (rpS6) Ser240/244 (#5364), p110α/PIK3CA (#4249),
and GAPDH (#2118) were from Cell Signaling technologies; Rictor (A300-
459A) was purchased from Bethyl Laboratories and Tubulin (T9026) was
from Sigma. All samples loaded in a corresponding gel derive from the
same experiment and were processed in parallel. Uncropped blots are
available in Figure S3.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections from the patient biopsy and
PDX were stained by immunohistochemistry (IHC) for CD56 (NCL-CD56-
aB6, Novocastra), KI67 (Dako) and p-AKT Ser473 (Cell Signaling technol-
ogies #3787). Citrate antigen retrieval was used. Incubation with primary
antibodies, according to manufacturer’s protocol, was followed by
incubation with HRP-coupled secondary antibodies and development
with diaminobenzidine and hematoxylin counterstaining following stan-
dard procedures25.
Statistical analysis
Statistical analysis was done with GraphPad Prism, the Mann–Whitney test
was used to assess differences between treatments; when P-value < 0.05,
differences were considered significant.
Data availability statement
All data generated or analyzed during this study are included in this
published article and its supplementary information files.
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